drugset / Trial / NCT06034860
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types. MT-8421 is an investigational drug that specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells in an effort to directly dismantle the tumor microenvironment for the treatment of patients with advanced solid tumors.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Outcome
Outcome not reported
Stopped: “Sponsor Termination”